Journal of Cardiovascular Emergencies 2017;3(2):61-71 REVIEW Cardiogenic shock (CS) remains the leading cause of death in patients hospitalized for acute myocardial infarction (AMI), occurring in 7% to 10% of AMI patients. [1] [2] [3] [4] In-hospital mortality rates for CS complicating AMI are reaching 50%, and short-term prognosis is linked to the severity of hemodynamic disturbances. 5 Several studies have suggested that short-term mortality in CS ranges between 42% and 48%, and that most patients will succumb due to multiple organ failure as a consequence of organ hypoperfusion. 
that illustrate such changes may be highly important for identifying the critical condition, leading to prompt therapeutic interventions, as well as for risk stratification. The aim of this article was to review the current literature data on complex biomarker assessment and monitoring of patients with AMI complicated with CS in the CCU.
SERum BIOmARkERS IN AmI COmPLICATED wITH CARDIOgENIC SHOCk
The most used biomarkers in acute cardiovascular settings include myocardial injury enzymes, parameters that express hemodynamic stress, systemic inflammation markers, as well as other emerging biomarkers such as extracellular matrix degradation indicators or micro-RNAs.
These biomarkers can be extremely important in monitoring response to treatment and for risk stratification in critical care conditions, helping to better guide the therapy of acute heart failure patients and leading to improvement in clinical management and outcomes. 15, 16 
Markers for Myocardial injury in the eMergency rooM
Creatine kinase (CK) is an enzyme that was described in 1965 as a biomarker for myocardial injury, having a sensitivity of 90%, but a low specificity for the detection of myocardial infarction. 17 CK is detected in the serum at 12
hours from the onset of myocardial damage, peaks in 24 to 35 hours and normalizes in 48 to 72 hours, this dynamic making it inappropriate for early diagnosis of AMI. Despite its low specificity (increasing as well in other conditions such as hemolysis, muscle damage, rhabdomyolysis, burns, trauma, sepsis, or pregnancy), the creatine kinase assay is still used for the diagnosis of AMI due to its relatively low costs and wide availability. 18, 19 CK-MB (creatine kinase -myocardium brain) is one of the three major isoenzymes of CK, found in high concentrations in the cardiac muscle, as well as in lower levels in the brain and skeletal muscles. 20 CK-MB presents similar releasing patterns to that of CK, and shows high specificity and sensitivity in detecting AMI, being more reliable in the 12-24-hour time window from the onset of AMI.
Nevertheless, CK-MB has been shown effective in identifying AMI patients presenting in the emergency department with acute chest pain with a nonspecific ECG, thus allowing timely reperfusion therapies. 21, 22 The current gold standard biomarker for myocardial infarction is considered to be cardiac troponin, which is highly specific for the cardiac muscle. 23 Troponin assays have become widely available and are used in cardiovascular emergency settings, as they allow the identification of acute myocardial infarction at 6 hours from the onset of symptoms, having a sensitivity of 80.75% and a specificity of 63.8%. 24, 25 The newer high-sensitivity assays can detect lower levels of troponin (3 pg/mL) within a shorter time from MI onset (3 to 4 hours from the onset of symptoms). 24 Despite its high diagnostic accuracy, false positive results may be encountered, caused by troponin elevation in conditions with increased oxygen demand, reduced cardiac output, or ventricular strain, such as heart failure, pulmonary embolism, or septic shock. 26 Other noncardiac causes for elevated troponin levels are anemia, renal failure, pulmonary disorders, ischemic and hemorrhagic cerebrovascular events, or intense exercise. 27, 28 Also, an increased level of troponin in heart failure patients has been linked to poorer outcomes, regardless of the presence of AMI, and elevated high-sensitive troponin expresses a considerably higher amount of myocardial injury in patients with heart failure, thus being a useful risk stratification biomarker. [29] [30] [31] Moreover, a sub-study of the Global Registry of Acute Coronary Events (GRACE) on 16,318 non-ST elevation myocardial infarction patients revealed that increased levels of troponin were associated with higher rates of cardiac arrest, new heart failure, cardiogenic shock, and death. 32 Myoglobin is a myocardial necrosis marker that can be detected in the blood stream within the first 3 hours from the onset of MI symptoms, but it lacks myocardial specificity, as it is raised in skeletal muscle damage, trauma, electrical cardioversion, renal disease, and patients with genetic muscular disorders. 19 The kinetics of plasmatic myoglobin levels have been shown to be a reliable way for assessing the coronary artery patency following thrombolytic therapy in MI patients; increased baseline levels of this enzyme were observed in patients who did not respond to streptokinase, while there was a significantly higher myoglobin release among responders to thrombolysis as compared to non-responders. Soluble ST 2 (sST2) is a novel marker expressing inflammation and interstitial fibrosis associated with heart failure that is up-regulated during myocardial strain as well as post-AMI. Soluble ST 2 has been shown to illustrate progressive decongestion in acute heart failure, and it has been demonstrated that circulating levels of sST2 decreased after 1 month in cases where mechanical circulatory assisting devices were used. [38] [39] [40] Natriuretic peptides (NP) with the 3 isoenzymes: atrial NP, brain NP (BNP), and NT-proBNP, act as protective hormones that counteract the physiologic abnormalities of myocardial dysfunction and injury. 41 BNP has also diagnostic and prognostic value in myocardial infarction, as a serum level higher than 30 pmol/L was shown to be highly sensitive for diagnosing AMI, with a negative predictive value of 96%. 42 Furthermore, BNP is an efficient risk stratification tool for short-and long-term major adverse cardiac events following an AMI. In combination with echocardiographic assessment of left ventricular ejection fraction, BNP leads to an increased predictive capacity for death, heart failure, and repeated ischemic episodes.
42,43
Co-peptin is a plasmatic peptide that increases in critical conditions such as shock, sepsis, stroke, or cardiovascular diseases, carrying diagnostic and prognostic value for myocardial injury. Persistently elevated levels of co-peptin after 3 to 5 days post-AMI are associated with higher rates of mortality and re-admissions for heart failure, and if associated with NT-proBNP assessment, it provides a more accurate risk prediction tool in AMI patients. 44, 45 inflaMMatory BioMarkers in acute coronary syndroMes and critical conditions
The systemic inflammatory response occurring in cardiogenic shock due to AMI is caused by myocardial necrosis, generalized tissue hypoperfusion, and hypoxia. 46 Several inflammatory cytokines, including interleukins (IL-6, IL8), tumor necrosis factor alpha (TNF-α), Creactive protein (CRP), and soluble adhesion molecules,
show increased levels in AMI complicated with CS.
47-49
The elevated baseline levels of inflammatory biomarkers have high predictive power for the development of CS and mortality in this patient population. A sub-study of the COMMA trial showed that increased values in the serum levels of IL-6, TNF-α, and CRP predicted the combined mortality and CS in AMI patients.
50
C-reactive protein is an acute inflammatory response protein that can be elevated in subjects with atherosclerosis. This biomarker expresses an enhanced inflammation, and is especially increased in acute coronary syndromes.
Furthermore, an increased level of CRP has been linked to worse outcomes following an acute coronary event.
51-56
Elevated plasmatic CRP concentrations are associated with the worsening of the hemodynamic and neurohormonal state of heart failure patients, being a valuable predictor for ischemic and non-ischemic complications. 57 Also, elevated levels of high-sensitive CRP (hs-CRP) have been associated with increased short-term death rates in AMI patients who underwent primary coronary angioplasty.
58-60
Interleukin-6 is the main promoter of CRP production at the level of the liver, being involved in acute inflammation, macrophage activity, hemato-and thrombopoiesis, and stem cell function. Also, the plasma concentration of IL-6 was shown to independently predict 30-day mortality in AMI patients with CS. 49 A study on 75 AMI patients who underwent primary angioplasty found significant correlations between increased levels of IL-6 and CRP and impairment of left ventricular systolic and diastolic function, as well as a good predictive power of these biomarkers for the development of systolic and diastolic dysfunction at 6 months.
61
Pentatraxin-3 (PTX-3) is a novel biomarker linked with the inflammatory response in heart failure patients, being shown to correlate with poor evolution of heart failure and with major adverse cardiac events in patients with known diastolic heart failure. 62,63 Also, PTX-3 levels have been proposed as prognostic markers for adverse events in patients with unstable angina and myocardial infarction. 64 Procalcitonin is an inflammatory response biomarker produced by the parathyroid gland, which has been correlated with the severity of organ injury in AMI and CS, being used as a guiding tool for treatment and risk stratification in severe heart failure patients. MMP-9, and MMP-7, which express an enhanced collagen turnover, were more increased in subjects with diastolic dysfunction. 77 According to the I-PRESERVE trial results, elevated levels of MMPs were associated with a higher incidence of the composite end-point of death due to heart failure, repeated hospitalizations, and all-cause mortality in patients with diastolic heart failure. 
HEmODYNAmIC mONITORINg IN THE CORONARY CARE uNIT
Various devices can be used in the CCUs, in order to pro- inefficient reperfusion therapy, which can serve as predictors for negative outcomes. [84] [85] [86] [87] [88] Furthermore, it has been demonstrated that more than three ischemic events, or more than one hour repeated ischemic event on the continuous ECG tracing records indicate a three-vessel coronary artery disease or severe coronary atherosclerosis. 84, 87, 88 The evaluation of arterial oxygen saturation with the use of pulse oximetry is used for noninvasively detecting the ventilatory status of the patients in the CCU. The technique is based on the photometric analysis of the pulse wave in the fingernail, requiring a systolic blood pressure of more than 85 mmHg. Therefore, clinical situations in which the patients present hypovolemia, low blood pressure, CS, or other types of shock associated with decreased tissular perfusion, can impair the evaluation of ventilatory status using this method. 89 Tissular hypoperfusion is the most common event that proceeds multiple organ dysfunction during shock. 90 Another method for the non- A normal urine output ranges between 0.5-1 mL/kg/h, while the presence of oliguria, a diuresis of less than 500 mL over a 24-hour period, might indicate a decreased renal perfusion that could be related to the onset of acute heart failure. 102, 103 The presence of oliguria in critically ill subjects with AMI is a sensitive marker of acute kidney injury, and it has been shown to be linked to higher mortality rates in these patients. 104, 105 Patients with CS secondary to AMI present decreased arterial pressure and an overall organ hypoperfusion, which leads to hypotensioninduced renal injury. The main cause of acute kidney insufficiency in critically ill AMI patients is acute circulatory failure, through a pre-renal mechanism. 106 A mean arterial pressure (MAP) of over 65 mmHg is required to avoid organ failures, including renal dysfunction. 107 An additional cause of renal dysfunction in patients with AMI is contrast-induced nephropathy, a complication of contrast media administration during coronary angiography and the third most common cause of hospital-acquired acute renal injury.
108

Monitoring heModynaMic status in the ccu
Usually, continuous recording of blood pressure and cardiac output (CO) is essential for the optimization of diuretic, inotropic, and vasodilator therapies in critical patients admitted in the CCU. 109 The finger-cuff technology can provide continuous noninvasive monitoring of BP and cardiac output, using a cuff placed around the finger for continuous BP measurement and beat-to-beat cardiac output calculation through pulse contouring. 110 Several studies have shown that this method is comparable to invasive monitoring systems.
111,112
The noninvasive evaluation of stroke volume and cardiac output can be achieved using thoracic electrical impedance, ultrasound, and pulse contour analysis. 113, 114 The parameters assessed with cardio-impedance methods are the fluid content of the thoracic cavity, which has a negative correlation with thoracic impedance, ventricular preload, and left ventricular contractility, thus allowing the estimation of cardiac output, systemic vascular resistance, and the overall mechanical function of the left ventricle. However, systems that use electrical impedance to estimate CO cannot be used in certain situations that include septic shock, aortic valve replacement, uncontrolled hypertension, arrhythmias, the presence of an intra-aortic balloon pump, body weight of more than 155 kg or less than 30 kg, as well as a heart rate above 200 beats per minute. [115] [116] [117] Pulse contour analysis systems are based on the fact that the area under the systolic segment of the arterial pulse wave is correlated with the stroke volume. 118 The first and most used device that uses pulse wave contour and thermo-dilution for CO evaluation is the minimally invasive PiCCO system (PULSION medical system, Munich, Germany), which requires a central venous line for cold saline injection and an arterial cannulation for placement of the temperature sensor that records the thermodilution curve. 119 In addition, the PiCCO system can assess intrathoracic blood volume, global enddiastolic volume, and extravascular lung water, allowing the measurement of cardiac preload and pulmonary edema quantification. 120 The Non-Invasive Cardiac Output (NICO) monitoring device is based on partial re-inhalation of CO 2 , using Fick's equation applied to carbon dioxide, and its accuracy is comparable to that of the gold standard thermodilution technique. 
